Clinical Trials Browser

Phase 1/2 × Neoplasm, Residual × Azacitidine × Clear all

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Phase 1/2 Terminated

24 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03699384 2019-02-20

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual